Mehrdad Golian

Mehrdad Golian

Auto-generated profile, based on publicly available information

Mehrdad Golian

Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2024 in Circulation
Verified
Journal Article
Closed access
BHBengt Herweg
Bengt Herweg
PSParikshit Sharma
Parikshit Sharma
ÓCÓscar Cano
Óscar Cano
SPShunmuga Sundaram Ponnusamy
Shunmuga Sundaram Ponnusamy
FZFrancesco Zanon
Francesco Zanon
PVPugazhendhi Vijayaraman
Pugazhendhi Vijayaraman
BACKGROUND: Left bundle branch area pacing (LBBAP) may be associated with greater improvement in left ventricular ejection fraction and reduction in death or heart failure hospitalization compared with biventricular pacing (BVP) in patients requiring cardiac resynchronization therapy. We sought to compare the occurrence of sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) and new-onset atrial fibrillation (AF) in patients undergoing BVP and LBBAP. METHODS: The I-CLAS study (International Collaborative LBBAP Study) included patients with left ventricular ejection fraction ≤35% who underwent BVP or LBBAP for cardiac resynchronization therapy between January 2018 and June 2022 at 15 centers. We performed propensity score–matched analysis of LBBAP and BVP in a 1:1 ratio. We assessed the incidence of VT/VF and new-onset AF among patients with no history of AF. Time to sustained VT/VF and time to new-onset AF was analyzed using the Cox proportional hazards survival model. RESULTS: Among 1778 patients undergoing cardiac resynchronization therapy (BVP, 981; LBBAP, 797), there were 1414 propensity score–matched patients (propensity score–matched BVP, 707; propensity score–matched LBBAP, 707). The occurrence of VT/VF was significantly lower with LBBAP compared with BVP (4.2% versus 9.3%; hazard ratio, 0.46 [95% CI, 0.29–0.74]; P 3 episodes in 24 hours) was also significantly lower with LBBAP compared with BVP (0.8% versus 2.5%; P =0.013). Among 299 patients with cardiac resynchronization therapy pacemakers (BVP, 111; LBBAP, 188), VT/VF occurred in 8 patients in the BVP group versus none in the LBBAP group (7.2% versus 0%; P 30 s was significantly lower with LBBAP than with BVP (2.8% versus 6.6%; hazard ratio, 0.34 [95% CI, 0.16–0.73]; P =0.008). The incidence of AF lasting >24 hours was also significantly lower with LBBAP than with BVP (0.7% versus 2.9%; P =0.015). CONCLUSIONS: LBBAP was associated with a lower incidence of sustained VT/VF and new-onset AF compared with BVP. This difference remained significant after adjustment for differences in baseline characteristics between patients with BVP and LBBAP. Physiological resynchronization by LBBAP may be associated with lower risk of arrhythmias compared with BVP.

15 December 2023 in Heart Rhythm
Verified
Journal Article
Open access
MGMehrdad Golian
Mehrdad Golian
NBNicolas M. Berbenetz
Nicolas M. Berbenetz
RORoupen Odabashian
Roupen Odabashian
MSMouhannad M. Sadek
Mouhannad M. Sadek
VCVicente Corrales-Medina
Vicente Corrales-Medina
DBDavid H. Birnie
David H. Birnie
Cardiac implantable electronic device (CIED) infection is a costly and highly morbid complication. Perioperative interventions, including the use of antibiotic pouches and intensified perioperative antibiotic regimens, have demonstrated marginal efficacy at reducing CIED infection. Additional research is needed to identify additional interventions to reduce infection risk. We sought to evaluate whether adherent skin barrier drape use is associated with a reduction in CIED infection. A prospective registry of all CIED implantation procedures was established at our institution in January 2007. The registry was established in collaboration with our hospital infection prevention team with a specific focus on prospectively identifying all potential CIED infections. All potential CIED infections were independently adjudicated by 2 physicians blinded to the use of an adherent skin barrier drape. Over a 13-year period, 14,225 procedures were completed (mean age 72 ± 14 years; female 4,918 (35%); new implants 10,005 (70%); pulse generator changes 2585 (18%); upgrades 1635 (11%). Of those, 2469 procedures (17.4%) were performed using an adherent skin barrier drape. There were 103 adjudicated device infections (0.73%). The infection rate in patients in the barrier use groups was 8 of 2469 (0.32%) as compared with 95 of 11,756 (0.8%) in the nonuse group (P = .0084). In multivariable analysis, the use of an adherent skin barrier drape was independently associated with a reduction in infection (odds ratio 0.32; 95% confidence interval 0.154–0.665; P = .002). The use of an adherent skin barrier drape at the time of cardiac device surgery is associated with a lower risk of subsequent infection.

14 February 2024 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
BCBenjamin J.W. Chow
Benjamin J.W. Chow
MCMatthew Cheung
Matthew Cheung
GPGraeme Prosperi-Porta
Graeme Prosperi-Porta
ATAnahita Tavoosi
Anahita Tavoosi
PMPouya Motazedian
Pouya Motazedian
MGMehrdad Golian
Mehrdad Golian

25 January 2023 in American Heart Journal
Verified
Journal Article
Closed access
MGMehrdad Golian
Mehrdad Golian
MSMouhannad M. Sadek
Mouhannad M. Sadek
AAAlper Aydin
Alper Aydin
DDDarryl Davis
Darryl Davis
MGMartin Green
Martin Green
DBDavid H. Birnie
David H. Birnie

9 August 2015 in Canadian Journal of Cardiology
Verified
Journal Article
Closed access
PDF file
MGMehrdad Golian
Mehrdad Golian
MMMotaz Moussa
Motaz Moussa
CWCharlene White
Charlene White
GAGiuseppe Aletta
Giuseppe Aletta
LKLillian Koley
Lillian Koley
CSColette Seifer
Colette Seifer

29 January 2026 in EP Europace
Verified
Journal Article
Open access
MGMehrdad Golian
Mehrdad Golian
ZLZhe Li
Zhe Li
NBNicolas M Berbenetz
Nicolas M Berbenetz
RORoupen Odabashian
Roupen Odabashian
MSMouhannad M Sadek
Mouhannad M Sadek
DBDavid H Birnie
David H Birnie
Aims: Cardiac implantable electronic device (CIED) infection carries a substantial burden of morbidity, mortality, and cost. The Prevention of Arrhythmia Device Infection Trial (PADIT) risk score improves identification of high-risk patients and may guide targeted strategies to reduce infection. Recent work has categorized CIED infection into localized pocket vs. systemic infection, with early reports suggesting different risk factors for each. However, no current risk score has been validated for infection subtypes. ObjectivesIndependently validate the PADIT infection risk score.Compare risk factors for infection subtypes.Assess PADIT performance in predicting subtype-specific infection. Methods and results: A prospective registry was initiated at the University of Ottawa Heart Institute in 2007 to capture all CIED procedures and prospectively identify infections in collaboration with the infection prevention team. PADIT risk score components were documented for each procedure. All suspected infections were adjudicated independently by two physicians (with a third if required), blinded to PADIT score and baseline variables, and subclassified as pocket or systemic infection. Logistic regression models were generated to validate PADIT performance for each subtype, with evaluation using Akaike and Bayesian information criteria (AIC/BIC), C-statistics, and calibration slope. Between 2007 and 2020, 14,225 procedures were performed (mean age 72 ± 14 years, 35% female, 70% new implants, 18% generator changes, 11% upgrades). A total of 103 infections (0.73%) were adjudicated, of which 71 (69%) were pocket and 32 (31%) systemic. The PADIT score showed good predictive performance with a C-statistic of 0.687 (95% CI 0.655–0.743), similar to the derivation cohort (0.702, 95% CI 0.661–0.741). Notably, the number of prior procedures was strongly associated with pocket infection but not systemic infection. PADIT discrimination was consistent across subtypes: pocket infection C-statistic 0.691 (95% CI 0.649–0.761) and systemic infection 0.746 (95% CI 0.707–0.848). Calibration slopes demonstrated good agreement between predicted and observed events, with the best fit for systemic infection. Conclusion: The PADIT score was independently validated with discrimination and calibration similar to the original derivation cohort. Importantly, prior procedures predicted pocket but not systemic infection. Overall, PADIT performed well in predicting both subtypes, with the strongest model fit observed for systemic infection.